OBJECTIVES:
Primary
To determine the response rate to capecitabine and oxaliplatin in patients with locally advanced or metastatic pancreatic adenocarcinoma Secondary
To determine safety
To determine overall survival
To determine time to progression
Developed by the Division of Clinical Informatics at Beth Israel Deaconess Medical Center, Alicanto™ is an online collaboration platform for learning, group collaborations, and clinical care coordination used at Harvard hospitals. Learn more at Alicanto Cloud.
Alicanto is developed by The Division of Clinical Informatics one of the first academic divisions in the world to concentrate on the use of computers for patient care, teaching, and medical research.
DCI is part of Beth Isreal Deaconess Medical Cented a world-class teaching hospital of Harvard Medical School located in the heart of Boston.
Powered by Alicanto Cloud and Opigno